Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and Europe. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company's lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, which are designed to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. In addition, its first-generation chronic total occlusion (CTO)-crossing catheters, Wildcat, and Kittycat 2, which employs a proprietary design that uses a rotational spinning technique allowing the physician to switch between passive and active modes when navigating across a CTO. The company sells and markets its products to interventional cardiologists, vascular surgeons, and interventional radiologists. Avinger, Inc. was founded in 2007 and is headquartered in Redwood City, California.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone650-241-7900
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$9.93 million
Profitability
Miscellaneous
Employees65
OptionableNot Optionable
Avinger (NASDAQ:AVGR) Frequently Asked Questions
What is Avinger's stock symbol?
Avinger trades on the NASDAQ under the ticker symbol "AVGR."
When did Avinger's stock split? How did Avinger's stock split work?
Avinger shares reverse split on Wednesday, January 31st 2018. The 1-40 reverse split was announced on Tuesday, January 30th 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 30th 2018. An investor that had 100 shares of Avinger stock prior to the reverse split would have 3 shares after the split.
How were Avinger's earnings last quarter?
Avinger Inc (NASDAQ:AVGR) released its quarterly earnings data on Tuesday, November, 13th. The medical device company reported ($0.56) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.51) by $0.05. The medical device company had revenue of $2.02 million for the quarter. View Avinger's Earnings History.
When is Avinger's next earnings date?
What is the consensus analysts' recommendation for Avinger?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avinger in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Avinger.
Has Avinger been receiving favorable news coverage?
Media coverage about AVGR stock has been trending somewhat positive this week, InfoTrie reports. The research firm identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Avinger earned a coverage optimism score of 1.6 on InfoTrie's scale. They also gave headlines about the medical device company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the near future.
Who are some of Avinger's key competitors?
Some companies that are related to Avinger include Nephros (NEPH), Restoration Robotics (HAIR), SANUWAVE Health (SNWV), Interpace Diagnostics Group (IDXG), PAVmed (PAVM), DarioHealth (DRIO), Lianluo Smart (LLIT), Neovasc (NVCN), Hancock Jaffe Laboratories (HJLI), Dynatronics (DYNT), Biostage (BSTG), Invivo Therapeutics (NVIV), Alliqua Biomedical (ALQA), Valeritas (VLRX) and Presbia (LENS).
Who are Avinger's key executives?
Avinger's management team includes the folowing people:
- Mr. Jeffrey M. Soinski, Pres, CEO & Director (Age 57)
- Mr. Mark B. Weinswig, Chief Financial Officer (Age 46)
- Mr. Keith Schaefer, Chief Operating Officer
- Mr. Himanshu N. Patel, Chief Technology Officer (Age 59)
- Mr. Philip R. Preuss, VP of Marketing & Bus. Operations (Age 41)
When did Avinger IPO?
(AVGR) raised $60 million in an initial public offering (IPO) on Friday, January 30th 2015. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Canaccord Genuity and Cowen and Company served as the underwriters for the IPO and Oppenheimer, BTIG and Stephens were co-managers.
Who are Avinger's major shareholders?
Avinger's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Virtu Financial LLC (1.08%) and CVI Holdings LLC (0.63%). Company insiders that own Avinger stock include Himanshu Patel and John B Ph D Md Simpson. View Institutional Ownership Trends for Avinger.
Which major investors are buying Avinger stock?
How do I buy shares of Avinger?
Shares of AVGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Avinger's stock price today?
One share of AVGR stock can currently be purchased for approximately $0.4389.
How big of a company is Avinger?
Avinger has a market capitalization of $10.30 million and generates $9.93 million in revenue each year. The medical device company earns $-48,730,000.00 in net income (profit) each year or ($70.07) on an earnings per share basis. Avinger employs 65 workers across the globe.
What is Avinger's official website?
How can I contact Avinger?
Avinger's mailing address is 400 CHESAPEAKE DRIVE, REDWOOD CITY CA, 94063. The medical device company can be reached via phone at 650-241-7900 or via email at [email protected]
MarketBeat Community Rating for Avinger (NASDAQ AVGR)
MarketBeat's community ratings are surveys of what our community members think about Avinger and other stocks. Vote "Outperform" if you believe AVGR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVGR will underperform the S&P 500 over the long term. You may vote once every thirty days.
